EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Vernalis paid £10 million ($13 million) to terminate its agreement with Tris Pharma. The decision follows regulatory setbacks for products covered by the agreement. Release (PDF)

> Syncona founded two gene therapy startups. The British life science investor committed $23 million to SwanBio and $12 million to Orbit Biomedical. Statement (PDF)

> Newron Pharmaceuticals delayed a readout from its phase 3 Rett syndrome clinical trial by up to six months. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> PharmaMar asked to change the primary endpoint of its phase 3 lung cancer trial. Moving from progression-free to overall survival will delay the readout until the second half of next year. Release (PDF)

> Motif Bio completed the rolling NDA for its antibiotic iclaprim. Statement